J&J sets sights on bigger Darzalex market with FDA 'breakthrough' in second-line myeloma

So far, the group of newly approved multiple myeloma meds hasn’t proved much of a threat to older, more established therapies. But that could all change soon.

Johnson & Johnson's Darzalex now has a chance to leapfrog into second-line use, a much bigger market than its current approved indication. The drug nabbed the FDA's Breakthrough Therapy Designation as a treatment for multiple myeloma patients who've relapsed after at least one prior therapy, the company said Tuesday.

In these patients, Darzalex would be combined with the chemo drug dexamethasone and either Celgene’s Revlimid or Takeda’s Velcade.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Right now, Darzalex is restricted to the fourth-line setting, meaning patients don’t get a crack at it until they’ve failed on three or more previous regimens. If this new designation leads to a speedy thumbs up from regulators, Darzalex’s patient pool will swell considerably--and bring in patients who tend to stay on therapy for longer periods of time.

It’s a prospect that would certainly please J&J, which is battling it out in the next-gen field with Takeda’s Ninlaro and Bristol-Myers Squibb and AbbVie’s Empliciti. All three meds were approved late last year, and so far they’ve been toiling with market shares in the single digits, Amgen commercial EVP Tony Hooper told investors on the company’s Q1 conference call.

But if J&J does snag a second-line nod, that'll put the heat on Amgen's Kyprolis, which only recently won its own second-line green light.  And stiffer competition is the last thing Kyprolis needs. The Big Biotech's med hasn't started off as strongly as Amgen had expected when it shelled out $10 billion for maker Onyx in 2013.

Meanwhile, J&J isn’t just relying on moving up into earlier lines of therapy to keep the Darzalex expansion coming. Earlier this year, J&J announced it would team up with Roche to test its cancer-fighter with Tecentriq, a brand-new PD-L1 immunotherapy from Roche’s Genentech unit.

- read J&J's release

Special Report: The top 15 pharma companies by 2014 revenue - Johnson & Johnson

Related Articles:
J&J's Darzalex slashes risk of myeloma progression by more than 60%
Amgen's Kyprolis stands its ground against new J&J, BMS rivals
Looking to build Darzalex a bigger market, J&J teams up with Roche for atezo combo trials
J&J undercuts Celgene's Pomalyst with $135K-per-year Darzalex price
Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti​
Amgen's Kyprolis wins 'backbone therapy' FDA nod after trumping Velcade in trial

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.